Aequus Pharmaceuticals Inc Share Price Toronto S.E.
Equities
CA0076361033
Pharmaceuticals
Sales 2022 | 13.8L 10.08L 8.42Cr | Sales 2023 | 3L 2L 1.56Cr | Capitalization | 33.16L 24.22L 20Cr |
---|---|---|---|---|---|
Net income 2022 | -30L -21.92L -18Cr | Net income 2023 | -20L -14.61L -12Cr | EV / Sales 2022 | 5.17 x |
Net Debt 2022 | 24.88L 18.18L 15Cr | Net Debt 2023 | 48.49L 35.42L 30Cr | EV / Sales 2023 | 32 x |
P/E ratio 2022 |
-1.45
x | P/E ratio 2023 |
-1.12
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 85.32% |
Managers | Title | Age | Since |
---|---|---|---|
Anne Stevens
FOU | Founder | - | 01/13/01 |
Douglas Janzen
CEO | Chief Executive Officer | 56 | 03/13/03 |
Ann Fehr
DFI | Director of Finance/CFO | 55 | 22/16/22 |
Members of the board | Title | Age | Since |
---|---|---|---|
Douglas Janzen
CEO | Chief Executive Officer | 56 | 03/13/03 |
Marc Lustig
BRD | Director/Board Member | 51 | 15/21/15 |
Director/Board Member | 54 | 18/14/18 |
1st Jan change | Capi. | |
---|---|---|
+42.60% | 75TCr | |
+33.03% | 60TCr | |
-5.74% | 36TCr | |
+17.79% | 33TCr | |
+3.37% | 28TCr | |
+16.96% | 24TCr | |
+8.83% | 21TCr | |
-4.38% | 21TCr | |
+6.74% | 16TCr |